Published in Ann Intern Med on June 18, 2013
A historic moment for open science: the Yale University Open Data Access project and medtronic. Ann Intern Med (2013) 1.45
Fracture healing: mechanisms and interventions. Nat Rev Rheumatol (2014) 1.33
Clinical trials registries are under-utilized in the conduct of systematic reviews: a cross-sectional analysis. Syst Rev (2014) 1.06
The clinical use of bone morphogenetic proteins revisited: a novel biocompatible carrier device OSTEOGROW for bone healing. Int Orthop (2013) 1.00
Antibiotics a cure for back pain, a false dawn or a new era? Eur Spine J (2013) 1.00
Meta-analysis of trials of recombinant human bone morphogenetic protein-2: what should spine surgeons and their patients do with this information? Ann Intern Med (2013) 0.99
Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2). Spine (Phila Pa 1976) (2013) 0.98
Biological aspects of segmental bone defects management. Int Orthop (2015) 0.93
The changing structure of industry-sponsored clinical research: pioneering data sharing and transparency. Ann Intern Med (2013) 0.91
Use of bone morphogenetic protein among patients undergoing fusion for degenerative diagnoses in the United States, 2002 to 2012. Spine J (2014) 0.90
Closing in on the truth about recombinant human bone morphogenetic protein-2: evidence synthesis, data sharing, peer review, and reproducible research. Ann Intern Med (2013) 0.89
Cancer risk from bone morphogenetic protein exposure in spinal arthrodesis. J Bone Joint Surg Am (2014) 0.87
Bone union rate with recombinant human bone morphogenic protein-2 versus autologous iliac bone in PEEK cages for anterior lumbar interbody fusion. Int Orthop (2014) 0.87
A Review of the Clinical Side Effects of Bone Morphogenetic Protein-2. Tissue Eng Part B Rev (2016) 0.87
Failure or success of search strategies to identify adverse effects of medical devices: a feasibility study using a systematic review. Syst Rev (2014) 0.85
Complications and cancer rates in spine fusion with recombinant human bone morphogenetic protein-2 (rhBMP-2). Eur Spine J (2015) 0.85
Trends analysis of rhBMP utilization in single-level posterior lumbar fusion (PLF) in the United States. Eur Spine J (2015) 0.84
A consensus statement regarding the utilization of BMP in spine surgery. Curr Rev Musculoskelet Med (2014) 0.84
Methylprednisolone for the Treatment of Patients with Acute Spinal Cord Injuries: A Systematic Review and Meta-Analysis. J Neurotrauma (2015) 0.83
Marshall R. Urist and the discovery of bone morphogenetic proteins. Int Orthop (2017) 0.83
Growth factors in orthopaedic surgery: demineralized bone matrix versus recombinant bone morphogenetic proteins. Int Orthop (2014) 0.82
Bone morphogenetic protein and orthopaedic surgery: can we legitimate its off-label use? Int Orthop (2014) 0.82
Trends in Bone Morphogenetic Protein Usage since the U.S. Food and Drug Administration Advisory in 2008: What Happens to Physician Practices When the Food and Drug Administration Issues an Advisory? Global Spine J (2013) 0.82
The controversy surrounding bone morphogenetic proteins in the spine: a review of current research. Yale J Biol Med (2014) 0.81
Insights in public health: perspectives on pain in the low back and neck: global burden, epidemiology, and management. Hawaii J Med Public Health (2014) 0.81
Methylprednisolone for the Treatment of Patients with Acute Spinal Cord Injuries: A Propensity Score-Matched Cohort Study from a Canadian Multi-Center Spinal Cord Injury Registry. J Neurotrauma (2015) 0.81
Structural & functional rehabilitation in eyes with lamina resorption following MOOKP--can the lamina be salvaged? Graefes Arch Clin Exp Ophthalmol (2014) 0.81
A meta analysis of lumbar spinal fusion surgery using bone morphogenetic proteins and autologous iliac crest bone graft. PLoS One (2014) 0.81
Prospective analysis of a new bone graft in lumbar interbody fusion: results of a 2- year prospective clinical and radiological study. Int J Spine Surg (2015) 0.80
Platelet concentrates in spine fusion: meta-analysis of union rates and complications in controlled trials. Eur Spine J (2015) 0.80
Systemically available bone morphogenetic protein two and seven affect bone metabolism. Int Orthop (2014) 0.80
A review of the current published spinal literature regarding bone morphogenetic protein-2: an insight into potential bias. Curr Rev Musculoskelet Med (2014) 0.79
Change in Off-Label Use of Bone Morphogenetic Protein in Spine Surgery and Associations with Adverse Outcome. Global Spine J (2016) 0.78
Clinical need for bone morphogenetic proteins. Int Orthop (2017) 0.78
Developments in intervertebral disc disease research: pathophysiology, mechanobiology, and therapeutics. Curr Rev Musculoskelet Med (2015) 0.78
Bone Regeneration from PLGA Micro-Nanoparticles. Biomed Res Int (2015) 0.78
Safety and efficacy of bioabsorbable cervical spacers and low-dose rhBMP-2 in multi-level ACDF. Int J Spine Surg (2014) 0.78
Formulation, Delivery and Stability of Bone Morphogenetic Proteins for Effective Bone Regeneration. Pharm Res (2017) 0.78
Non-union rate with stand-alone lateral lumbar interbody fusion. Medicine (Baltimore) (2014) 0.77
Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway. Proc Natl Acad Sci U S A (2015) 0.76
RhBMP-2 Activates Hippo Signaling through RASSF1 in Esophageal Cancer Cells. Sci Rep (2016) 0.76
The role of stem cell therapies in degenerative lumbar spine disease: a review. Neurosurg Rev (2015) 0.76
How do you know it is true? Integrity in research and publications: AOA critical issues. J Bone Joint Surg Am (2015) 0.75
Biologic enhancement of spinal fusion with bone morphogenetic proteins: current position based on clinical evidence and future perspective. J Spine Surg (2016) 0.75
Bone Morphogenic Protein Is a Viable Adjunct for Fusion in Minimally Invasive Transforaminal Lumbar Interbody Fusion. Asian Spine J (2016) 0.75
Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: a protocol for a systematic review. Syst Rev (2015) 0.75
A Review and Analysis of the YODA Trials: What Can We Glean Clinically? Curr Rev Musculoskelet Med (2014) 0.75
BMP-2-induced bone formation and neural inflammation. J Orthop (2017) 0.75
mTOR inhibition and BMP signaling act synergistically to reduce muscle fibrosis and improve myofiber regeneration. JCI Insight (2016) 0.75
Credibility matters: mind the gap. Evid Based Spine Care J (2014) 0.75
Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases. Oncotarget (2016) 0.75
Moving forward from rhBMP-2: open science and data sharing. Spine (Phila Pa 1976) (2014) 0.75
Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project. Syst Rev (2017) 0.75
A Retrospective Analysis of Complications Associated With Bone Morphogenetic Protein 2 in Anterior Lumbar Interbody Fusion. Global Spine J (2017) 0.75
The potential impact of bone tissue engineering in the clinic. Regen Med (2016) 0.75
The role of peptides in bone healing and regeneration: a systematic review. BMC Med (2016) 0.75
Preliminary Results of Bioactive Amniotic Suspension with Allograft for Achieving One and Two-Level Lumbar Interbody Fusion. Int J Spine Surg (2016) 0.75
Comparison of rhBMP-2 versus Autogenous Iliac Crest Bone Graft for 2-Level Anterior Cervical Discectomy and Fusion for Cervical Spondylotic Myelopathy. Med Sci Monit (2015) 0.75
Cochrane in CORR1: Steroids for Acute Spinal Cord Injury (Review). Clin Orthop Relat Res (2016) 0.75
Epidemiologic trends in the utilization, demographics, and cost of bone morphogenetic protein in spinal fusions. Curr Rev Musculoskelet Med (2014) 0.75
Spine Wars: The Lessons of YODA. Evid Based Spine Care J (2013) 0.75
Use of OP-1 (rhBMP-7) in posterolateral lumbar arthrodesis. J Spine Surg (2016) 0.75
Bone morphogenetic protein in adult spinal deformity surgery: a meta-analysis. Eur Spine J (2017) 0.75
Market approval processes for new types of spinal devices: challenges and recommendations for improvement. Eur Spine J (2016) 0.75
Comparison of a calcium phosphate bone substitute with recombinant human bone morphogenetic protein-2: a prospective study of fusion rates, clinical outcomes and complications with 24-month follow-up. Eur Spine J (2016) 0.75
Trends Analysis of rhBMP Utilization in Single-Level Posterior Lumbar Interbody Fusion in the United States. Global Spine J (2017) 0.75
Sulfated glycopeptide nanostructures for multipotent protein activation. Nat Nanotechnol (2017) 0.75
Practical methods for incorporating summary time-to-event data into meta-analysis. Trials (2007) 14.51
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev (2015) 11.05
How should meta-regression analyses be undertaken and interpreted? Stat Med (2002) 8.96
Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol (2007) 7.00
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ (2011) 6.80
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Evaluation of networks of randomized trials. Stat Methods Med Res (2007) 4.70
Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med (2008) 4.34
Interpretation of random effects meta-analyses. BMJ (2011) 4.32
Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol (2002) 4.30
Investigating patient exclusion bias in meta-analysis. Int J Epidemiol (2004) 3.90
A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol (2006) 3.78
Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet (2007) 3.53
Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. BMJ (2006) 3.47
A road map for efficient and reliable human genome epidemiology. Nat Genet (2006) 3.21
Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials (2005) 3.19
To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data. Eval Health Prof (2002) 3.11
Recent developments in meta-analysis. Stat Med (2008) 2.97
Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66,155 cases and 91,307 controls. Lancet (2006) 2.72
Graphical tools for network meta-analysis in STATA. PLoS One (2013) 2.66
Synthesizing evidence on complex interventions: how meta-analytical, qualitative, and mixed-method approaches can contribute. J Clin Epidemiol (2013) 2.59
Strengthening the reporting of genetic association studies (STREGA): an extension of the strengthening the reporting of observational studies in epidemiology (STROBE) statement. J Clin Epidemiol (2009) 2.45
STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med (2009) 2.39
A case study of multiple-treatments meta-analysis demonstrates that covariates should be considered. J Clin Epidemiol (2009) 2.26
Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer (2005) 2.16
Genome-wide association studies, field synopses, and the development of the knowledge base on genetic variation and human diseases. Am J Epidemiol (2009) 2.15
Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit? Lancet (2005) 2.09
Array CGH in patients with learning disability (mental retardation) and congenital anomalies: updated systematic review and meta-analysis of 19 studies and 13,926 subjects. Genet Med (2009) 2.09
Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis. BMC Med Res Methodol (2011) 1.97
Conceptual and technical challenges in network meta-analysis. Ann Intern Med (2013) 1.92
STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. Eur J Clin Invest (2009) 1.82
A novel tool for the assessment of pain: validation in low back pain. PLoS Med (2009) 1.75
Evaluation of inconsistency in networks of interventions. Int J Epidemiol (2013) 1.72
Obstacles and opportunities in meta-analysis of genetic association studies. Genet Med (2005) 1.71
Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis. Am J Epidemiol (2008) 1.71
Assessing the impact of drinking water and sanitation on diarrhoeal disease in low- and middle-income settings: systematic review and meta-regression. Trop Med Int Health (2014) 1.64
Hygiene and health: systematic review of handwashing practices worldwide and update of health effects. Trop Med Int Health (2014) 1.63
The emergence of networks in human genome epidemiology: challenges and opportunities. Epidemiology (2007) 1.61
Systematic reviews of genetic association studies. Human Genome Epidemiology Network. PLoS Med (2009) 1.60
Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS One (2012) 1.50
The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol (2010) 1.49
Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE Statement. Hum Genet (2009) 1.47
Epidural fentanyl for postoperative analgesia after lumbar canal decompression: a randomized controlled trial. Spine J (2012) 1.47
Hsp27 upregulation and phosphorylation is required for injured sensory and motor neuron survival. Neuron (2002) 1.46
A network of investigator networks in human genome epidemiology. Am J Epidemiol (2005) 1.43
Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol (2011) 1.42
Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists. Epidemiology (2017) 1.38
Portion, package or tableware size for changing selection and consumption of food, alcohol and tobacco. Cochrane Database Syst Rev (2015) 1.37
Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev (2014) 1.36
Five glutathione s-transferase gene variants in 23,452 cases of lung cancer and 30,397 controls: meta-analysis of 130 studies. PLoS Med (2006) 1.35
The impact of study size on meta-analyses: examination of underpowered studies in Cochrane reviews. PLoS One (2013) 1.32
Strengthening the reporting of genetic association studies (STREGA): an extension of the STROBE statement. Eur J Epidemiol (2009) 1.25
Estimating within-study covariances in multivariate meta-analysis with multiple outcomes. Stat Med (2012) 1.23
A design-by-treatment interaction model for network meta-analysis with random inconsistency effects. Stat Med (2014) 1.21
STrengthening the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE statement. Genet Epidemiol (2009) 1.13
STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE Statement. Ann Intern Med (2009) 1.11
Allowing for uncertainty due to missing data in meta-analysis--part 1: two-stage methods. Stat Med (2008) 1.10
Challenges in the use of literature-based meta-analysis to examine gene-environment interactions. Am J Epidemiol (2010) 1.10
Bayesian meta-analysis and meta-regression for gene-disease associations and deviations from Hardy-Weinberg equilibrium. Stat Med (2007) 1.09
Bayesian multivariate meta-analysis with multiple outcomes. Stat Med (2013) 1.08
Planning future studies based on the conditional power of a meta-analysis. Stat Med (2012) 1.05
Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol (2012) 1.01
Turning the pump handle: evolving methods for integrating the evidence on gene-disease association. Am J Epidemiol (2007) 1.01
Quantitative proteomics using stable isotope labeling with amino acids in cell culture reveals changes in the cytoplasmic, nuclear, and nucleolar proteomes in Vero cells infected with the coronavirus infectious bronchitis virus. Mol Cell Proteomics (2010) 1.00
Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis. Stat Med (2014) 0.98
Systematic review of controlled trials on the effectiveness of fluoride gels for the prevention of dental caries in children. J Dent Educ (2003) 0.97
Systematic review and meta-analysis of the value of initial biomarkers in predicting adverse outcome in febrile neutropenic episodes in children and young people with cancer. BMC Med (2012) 0.97
Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropaenic episodes in children and young people. Eur J Cancer (2010) 0.97
Publication bias and meta-analyses: a practical example. Int J Technol Assess Health Care (2003) 0.97
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev (2015) 0.96
Response to paper by Lang A, Edwards N, and Fleiszer A. J Clin Epidemiol (2007) 0.95
Meta-analysis and subgroups. Prev Sci (2013) 0.95
Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. BMJ (2009) 0.93
Meta-analysis of genetic association studies under different inheritance models using data reported as merged genotypes. Stat Med (2008) 0.91
Online genetic databases informing human genome epidemiology. BMC Med Res Methodol (2007) 0.91
Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. BMJ (2011) 0.90
Allowing for uncertainty due to missing data in meta-analysis--part 2: hierarchical models. Stat Med (2008) 0.90
The cellular interactome of the coronavirus infectious bronchitis virus nucleocapsid protein and functional implications for virus biology. J Virol (2013) 0.90
Allowing for uncertainty due to missing continuous outcome data in pairwise and network meta-analysis. Stat Med (2014) 0.88
Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-analysis. BMC Res Notes (2012) 0.86
Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int J Epidemiol (2002) 0.86
Summarising and validating test accuracy results across multiple studies for use in clinical practice. Stat Med (2015) 0.85
Complications from minimally invasive lumbar interbody fusion: experience from 100 patients. J Clin Neurosci (2013) 0.85
Comments on 'Empirical vs natural weighting in random effects meta-analysis'. Stat Med (2010) 0.83
Cognitive-behavioural interventions for children who have been sexually abused. Cochrane Database Syst Rev (2012) 0.83
Characteristics of a loop of evidence that affect detection and estimation of inconsistency: a simulation study. BMC Med Res Methodol (2014) 0.82
Meta-analysis in occupational epidemiology: a review of practice. Occup Med (Lond) (2004) 0.82
Relative efficacy of differential methods of dietary advice: a systematic review. Am J Clin Nutr (2003) 0.82
Predicting infectious complications in neutropenic children and young people with cancer (IPD protocol). Syst Rev (2012) 0.80
Glutamine supplementation to prevent morbidity and mortality in preterm infants. Cochrane Database Syst Rev (2016) 0.80
WITHDRAWN: Opioids for the palliation of breathlessness in advanced disease and terminal illness. Cochrane Database Syst Rev (2012) 0.80
The impact of trial characteristics on premature discontinuation of antipsychotics in schizophrenia. Eur Neuropsychopharmacol (2013) 0.80
Two-stage meta-analysis of survival data from individual participants using percentile ratios. Stat Med (2012) 0.80
Response to: Practical methods for incorporating summary time-to-event data into meta. Authors' reply. Trials (2013) 0.79